TY - JOUR
T1 - Clinical utility of biochemical markers of bone metabolism for improving the management of patients with advanced multiple myeloma
AU - Lipton, Allan
AU - Cook, Richard J.
AU - Coleman, Robert E.
AU - Smith, Matthew R.
AU - Major, Pierre
AU - Terpos, Evangelos
AU - Berenson, James R.
N1 - Funding Information:
1Division of Oncology, Penn State University Milton S. Hershey Medical Center, PA 2University of Waterloo, Ontario, Canada 3Cancer Research Centre, Academic Unit of Clinical Oncology, Weston Park Hospital, Sheffield, United Kingdom 4Massachusetts General Hospital, Boston 5Hamilton Regional Cancer Centre, Ontario, Canada 6Department of Hematology and Medical Research, 251 General Airforce Hospital, Athens, Greece 7Institute for Myeloma and Bone Cancer Research, West Hollywood, CA
PY - 2007/3
Y1 - 2007/3
N2 - Osteolytic bone lesions from advanced multiple myeloma (MM) result in significant skeletal morbidity. Therefore, biochemical markers of bone metabolism, such as the N-terminal and C-terminal telopeptides of type I collagen, bone-specific alkaline phosphatase, and osteocalcin, have been investigated as tools for evaluating the extent of bone disease, risk of skeletal morbidity, and response to antiresorptive treatment. Several studies have shown that the majority of biochemical markers of bone metabolism are increased in patients with MM with osteolytic bone lesions, thus reflecting changes in bone metabolism associated with tumor growth. There is also a growing body of evidence that markers of bone metabolism correlate with the risk of skeletal complications, disease progression, and death. In addition, bone markers could potentially be used as a tool for early diagnosis of bone lesions. The aim of this review is to improve our understanding of bone markers as a clinical tool for the management of malignant bone disease in patients with MM.
AB - Osteolytic bone lesions from advanced multiple myeloma (MM) result in significant skeletal morbidity. Therefore, biochemical markers of bone metabolism, such as the N-terminal and C-terminal telopeptides of type I collagen, bone-specific alkaline phosphatase, and osteocalcin, have been investigated as tools for evaluating the extent of bone disease, risk of skeletal morbidity, and response to antiresorptive treatment. Several studies have shown that the majority of biochemical markers of bone metabolism are increased in patients with MM with osteolytic bone lesions, thus reflecting changes in bone metabolism associated with tumor growth. There is also a growing body of evidence that markers of bone metabolism correlate with the risk of skeletal complications, disease progression, and death. In addition, bone markers could potentially be used as a tool for early diagnosis of bone lesions. The aim of this review is to improve our understanding of bone markers as a clinical tool for the management of malignant bone disease in patients with MM.
UR - http://www.scopus.com/inward/record.url?scp=34248143552&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34248143552&partnerID=8YFLogxK
U2 - 10.3816/CLM.2007.n.011
DO - 10.3816/CLM.2007.n.011
M3 - Review article
C2 - 17562244
AN - SCOPUS:34248143552
SN - 1557-9190
VL - 7
SP - 346
EP - 353
JO - Clinical Lymphoma and Myeloma
JF - Clinical Lymphoma and Myeloma
IS - 5
ER -
